BMT
Asset Logo

Beamtree Holdings Limited

πŸ‡¦πŸ‡Ί ASX

🩺 HEALTH CARE

πŸ“ˆ HIGH PRICE GROWTH

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

+ 12.73%
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

6
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Beamtree Holdings Ltd. is an Australian healthcare technology company, which engages in the proprietary subscription based CDS called RippleDown that automates the human decision-making process within healthcare organizations based on rules set within the organization by domain experts. The company is headquartered in Sydney, New South Wales and currently employs 97 full-time employees. The company went IPO on 2019-06-06. The firm provides automation technology and data analytics that support health care providers. The firm's segments include diagnostic technology, clinical decision support, coding assistance and data quality, analytics and knowledge networks. The diagnostic technology segment includes its RippleDown products, which automate decision making in clinical and administrative processes in pathology. Its automation of clinical record coding and data integrity products include its RippleDown and Performance Indicators for Coding Quality coding technologies (PICQ). Its clinical decision support segment includes Ainsoff Deterioration Index, which is a machine learning-based tool that predicts the risk of patient deterioration and alerts clinicians in real time. Its products also include advisory and auditing, Q coding platform, and Relative Indicators for Safety and Quality.

πŸ“ˆ Performance

Price History

+35.00%

1M

1Y

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.27

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in BMT

6

πŸ“Š Total Capital Earnings

$5K

πŸ”ƒ Average investment frequency

17 weeks

πŸ’΅ Average investment amount

$542

⏰ Last time a customer invested in BMT

219 days
BMT investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

40%

50k - 100k

30%

Less than 50k

20%
πŸ‘Ά Age of investors

18 - 25

26 - 34

33%

35 - 90

67%
πŸ™‹ Legal gender of investors

Female

50%

Male

50%

Pearlers who invest in BMT also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

3.62%

πŸ“Š Share price

$102.10 AUD

πŸ‡¦πŸ‡Ί AUSTRALIA

⛳️ DIVERSIFIED

🧱 MATERIALS

πŸ’Έ FINANCIALS

Find Out More

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

πŸ™Œ Performance (5Yr p.a)

4.67%

πŸ“Š Share price

$0.04 AUD

🧬 BIOTECHNOLOGY

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

πŸ™Œ Performance (5Yr p.a)

20.56%

πŸ“Š Share price

$63.57 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ‡ΊπŸ‡Έ UNITED STATES

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

14.02%

πŸ“Š Share price

$140.20 AUD

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

🌏 GLOBAL

πŸ€– TECHNOLOGY

Atturra Ltd. engages in the provision of information technology solutions and services. The company is headquartered in Sydney, New South Wales and currently employs 900 full-time employees. The company went IPO on 2021-12-22. The firm is engaged in the technology business, providing a range of enterprise advisory, consulting, information technology (IT) services and solutions with a focus on local government, utilities, education, defense, federal government, financial services, and manufacturing industries. Its advisory and consulting capabilities across three areas include strategy and preparation, design and implementation, and realization and improvement. Its business applications capabilities include enterprise resource planning, process optimization for local government, payroll systems consulting, safety solutions, and others. Its data and integration capabilities include intelligent integration and automation, enterprise data management, advanced analytics, middleware modernization, and others. Its managed services include cloud and infrastructure, modern workplace, enterprise network services, and others.

πŸ“Š Share price

$1.02 AUD

πŸ€– TECHNOLOGY

Want more shares? Try these...

BNDS.AX was created on 2018-11-07 by BetaShares. The fund's investment portfolio concentrates primarily on broad credit fixed income. The Fund aims to earn an after fee return in excess of the Bloomberg AusBond Composite 0+yr Index over rolling three year periods.

πŸ™Œ Performance (5Yr p.a)

-2.46%

πŸ“Š Share price

$23.55 AUD

BNKS.AX was created on 2016-07-28 by BetaShares. The fund's investment portfolio concentrates primarily on financials equity. BNKS.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global banks (ex-Australia), hedged into Australian dollars.

πŸ™Œ Performance (5Yr p.a)

4.23%

πŸ“Š Share price

$8.48 AUD

🌏 GLOBAL

πŸ“Š Share price

$0.00 AUD

Ballymore Resources Ltd. engages in the identification, development, and exploration of mineral resources. The company is headquartered in Brisbane, Queensland. The company went IPO on 2021-09-03. The firm holds a portfolio of exploration and development projects in the Queensland mineral belts that are prospective for gold and base metals. These consist of about two granted Mining Leases (MLs), 14 Exploration Permits over four project areas at Dittmer, Ruddygore, Ravenswood, and Mount Molloy. The total area covered by the tenements is approximately 1,456 square kilometers. The Dittmer Project is located 20 kilometers (km) west of Proserpine in Central Queensland and comprises two granted MLs, one ML application and three granted EPMs covering an area of 513 square kilometers. The Ruddygore Project is located adjacent to the town of Chillagoe in North Queensland and approximately 150 km west of Cairns. The Ravenswood Project covers an area of about 309 square kilometers and is located to the south and east of Charters Towers. The Mount Molloy Project is located south of the town of Mount Molloy.

πŸ“Š Share price

$0.13 AUD

⛏️ MINING

Compare
Add to watchlist